[Strontium ranlelate (Protelos)].
Strontium ranelate, with its unique mode of action combining inhibition of bone resorption and stimulation of bone formation is characterized by a wide scatter of activity, both in terms of skeletal sites positively affected and of patients experiencing benefits of its administration. It is currently reimbursed, in Belgium, in osteoporotic patients aged 80 years and older. In this group, it is the only drug which has shown an extensive range of anti-fracture efficacy.
Reginster
J Y
JY
Service de Santé Publique, Epidémiologie et Economie de la Santé, ULg, CHU Sart Tilman, Liège. jyreginster@ulg.ac.be
D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D009942:Organometallic Compounds / Q000494:pharmacology*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D013876:Thiophenes / Q000494:pharmacology*
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate